DC Black Label
DC Black Label is an imprint of American comic book publisher DC Comics. It was established in 2018 to publish mature readers content that is outside the continuity of the DC Universe. The imprint allows writers and artists to explore darker and more complex themes without the constraints of the main DC continuity.
History
DC Black Label was announced in March 2018 as a way to give creators the freedom to tell stories that are more mature and sophisticated. The imprint was designed to attract both new and established talent to create standalone stories featuring DC's iconic characters. The first title released under the DC Black Label imprint was Batman: Damned, written by Brian Azzarello and illustrated by Lee Bermejo.
Notable Titles
Some of the notable titles published under the DC Black Label imprint include:
- Batman: Damned
- Superman: Year One by Frank Miller and John Romita Jr.
- Wonder Woman: Dead Earth by Daniel Warren Johnson
- Harleen by Stjepan Šejić
- The Question: The Deaths of Vic Sage by Jeff Lemire, Denys Cowan, and Bill Sienkiewicz
Characteristics
DC Black Label titles are known for their high production values, including premium paper stock and larger trim sizes. The stories often explore mature themes such as violence, sexuality, and psychological depth, making them suitable for an adult audience. The imprint also allows for more creative freedom, enabling writers and artists to reinterpret classic characters and storylines in new and innovative ways.
Impact
The launch of DC Black Label has been met with both critical acclaim and controversy. Batman: Damned garnered significant attention for its mature content, leading to discussions about the boundaries of mainstream comic book publishing. Despite some controversies, the imprint has been praised for its high-quality storytelling and artistic innovation.
Related Pages
- DC Comics
- Vertigo (DC Comics)
- Batman: Damned
- Superman: Year One
- Wonder Woman: Dead Earth
- Harleen
- The Question: The Deaths of Vic Sage
Categories
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD